Study Summary
This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to target mesothelin and express PD-1 antibodies in adult patients with advanced recurrent or refractory malignant solid tumors, which were positive expression of mesothelin.
Want to learn more about this trial?
Request More InfoInterventions
PD-1 antibody expressing mesoCAR-T cellsBIOLOGICAL
Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| China | Shanghai | Shanghai Municipality | China |